Literature DB >> 24189118

Impact of inflammation on neurotransmitter changes in major depression: an insight into the action of antidepressants.

Brian E Leonard1.   

Abstract

This review summarises the evidence that chronic low grade inflammation plays an important role in the pathology of depression. Evidence is provided that pro-inflammatory cytokines, together with dysfunctional endocrine and neurotransmitter systems, provide a network of changes that underlie depression and may ultimately contribute to the neurodegenerative changes that characterise depression in the elderly. Antidepressants attenuate the inflammatory changes and hypercortisolaemia by reducing the release of the pro-inflammatory cytokines from activated microglia, and by sensitizing the glucocorticoids receptors in the HPA axis. These effects correlate with an improvement in monoamine neurotransmitter function. The possible mechanisms whereby this cascade of changes occurs are outlined. In conclusion, the mechanisms whereby antidepressants act should now consider the involvement of the immune and endocrine systems in addition to the central neurotransmitters. This may open up possibilities for a new generation of antidepressants in the future.
© 2013.

Entities:  

Keywords:  Antidepressants; Cytokines; Depression; Inflammation

Mesh:

Substances:

Year:  2013        PMID: 24189118     DOI: 10.1016/j.pnpbp.2013.10.018

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  32 in total

Review 1.  A mitochondrial bioenergetic basis of depression.

Authors:  N Jennifer Klinedinst; William T Regenold
Journal:  J Bioenerg Biomembr       Date:  2014-09-28       Impact factor: 2.945

2.  Markers of inflammation in schizophrenia: association vs. causation.

Authors:  Peter Manu; Christoph U Correll; Martien Wampers; Alex J Mitchell; Michel Probst; Davy Vancampfort; Marc De Hert
Journal:  World Psychiatry       Date:  2014-06       Impact factor: 49.548

3.  Prevention of unpredictable chronic stress-related phenomena in zebrafish exposed to bromazepam, fluoxetine and nortriptyline.

Authors:  Matheus Marcon; Ana P Herrmann; Ricieri Mocelin; Cassiano L Rambo; Gessi Koakoski; Murilo S Abreu; Greicy M M Conterato; Luiza W Kist; Maurício R Bogo; Leila Zanatta; Leonardo J G Barcellos; Angelo L Piato
Journal:  Psychopharmacology (Berl)       Date:  2016-08-25       Impact factor: 4.530

4.  Identification of Genetic Variations in the NAD-Related Pathways for Patients with Major Depressive Disorder: A Case-Control Study in Taiwan.

Authors:  Daniel Tzu-Li Chen; Szu-Wei Cheng; Tiffany Chen; Jane Pei-Chen Chang; Bing-Fang Hwang; Hen-Hong Chang; Eric Y Chuang; Che-Hong Chen; Kuan-Pin Su
Journal:  J Clin Med       Date:  2022-06-23       Impact factor: 4.964

5.  Effects of Huolisu Oral Solution on Depression-Like Behavior in Rats: Neurotransmitter and HPA Axis.

Authors:  Min Xiao; Kaiyong Xie; Li Yuan; Jun Wang; Xing Liu; Zhonghua Chen
Journal:  Front Pharmacol       Date:  2022-06-02       Impact factor: 5.988

6.  Altered B Cell Homeostasis in Patients with Major Depressive Disorder and Normalization of CD5 Surface Expression on Regulatory B Cells in Treatment Responders.

Authors:  Diana Ahmetspahic; Kathrin Schwarte; Oliver Ambrée; Christian Bürger; Vladislava Falcone; Katharina Seiler; Mehrdad Rahbar Kooybaran; Laura Grosse; Fernand Roos; Julia Scheffer; Silke Jörgens; Katja Koelkebeck; Udo Dannlowski; Volker Arolt; Stefanie Scheu; Judith Alferink
Journal:  J Neuroimmune Pharmacol       Date:  2017-09-13       Impact factor: 4.147

7.  Arctigenin protects against depression by inhibiting microglial activation and neuroinflammation via HMGB1/TLR4/NF-κB and TNF-α/TNFR1/NF-κB pathways.

Authors:  Xiang Xu; Hu-Nan Piao; Fumie Aosai; Xiao-Yu Zeng; Jia-Hui Cheng; Yue-Xian Cui; Jing Li; Juan Ma; Hu-Ri Piao; Xuejun Jin; Lian-Xun Piao
Journal:  Br J Pharmacol       Date:  2020-10-19       Impact factor: 8.739

8.  Indoleamine-2,3-Dioxygenase/Kynurenine Pathway as a Potential Pharmacological Target to Treat Depression Associated with Diabetes.

Authors:  Isabella Caroline da Silva Dias; Bruno Carabelli; Daniela Kaori Ishii; Helen de Morais; Milene Cristina de Carvalho; Luiz E Rizzo de Souza; Silvio M Zanata; Marcus Lira Brandão; Thiago Mattar Cunha; Anete Curte Ferraz; Joice Maria Cunha; Janaina Menezes Zanoveli
Journal:  Mol Neurobiol       Date:  2015-12-15       Impact factor: 5.590

Review 9.  IDO and TDO as a potential therapeutic target in different types of depression.

Authors:  Yanjie Qin; Nanxi Wang; Xinlin Zhang; Xuemei Han; Xuejia Zhai; Yongning Lu
Journal:  Metab Brain Dis       Date:  2018-07-16       Impact factor: 3.584

10.  Vagus Nerve Stimulation.

Authors:  Robert H Howland
Journal:  Curr Behav Neurosci Rep       Date:  2014-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.